Prognostics

Tumor Recurrence Best Survival Predictor After PEI Therapy

Published in Hepatitis Weekly, August 6th, 2001

by Sonia Nichols, senior medical writer - Individuals with cirrhosis who do not develop cancer recurrence after percutaneous ethanol injection (PEI) therapy for primary liver cancer tend to survive longer than those with recurrences do.

Furthermore, pretreatment values for liver activity, liver cancer markers, and platelet counts are predictive of post-treatment survival in patients who receive this therapy, according to medical investigators in Italy.

During PEI therapy, doctors use imaging techniques to guide a needle directly into the core of a tumor. They then inject ethanol into that core, killing the malignant cells. Multiple PEI therapy...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2001-08-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry